Phase I Single-blind Clinical Trial to Evaluate the Safety and Local Immune Activation of a Toll-like Receptor 5 Agonist (FLAMOD) Administered by Aerosol

Inclusion Criteria: * provision of signed and dated informed consent form * stated willingness to comply with all trial procedures, clinic visits, blood draws, and availability for the duration of the trial * human subjects who are between 18 and 65 years of age * weight of at least 50 kg and body mass index (BMI) within the range of 18 - 30 kg/m² * females of non-childbearing potential or of childbearing potential with effective contraception, males willing to practice contraception or having a partner using contraception (if having heterosexual intercourse) * non-smoker subject (included e-cigarette smoking) since at least 3 months and able to not smoke during the whole trial * maximum alcohol consumption defined as: i. no more than ten standard glasses per week; ii. no more than two standard glasses per day; iii. having alcohol-free day during the week * volunteer should be healthy after a clinical examination * affiliation with a social security scheme or beneficiary of such a scheme Exclusion Criteria: * febrile and/or suspected infection * history of chronic pulmonary disease * history of acute pulmonary disease in the past 6 months * immunocompromised individuals, which includes immunodeficient patients (e.g., those with asplenism, acquired immune deficiency syndrome, or immunoglobulin deficiencies), patients with haematological diseases or solid cancers, solid organ or stem-cell transplant recipients, as well as patients with other conditions requiring immunosuppre…